97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-001430-33-DE (EUCTR) | 18/06/2020 | 25/02/2020 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | Canada;Belgium;Poland;Australia;Germany;United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic | ||
| 2 | EUCTR2019-001430-33-PL (EUCTR) | 20/05/2020 | 28/02/2020 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany | ||
| 3 | EUCTR2019-001430-33-AT (EUCTR) | 15/05/2020 | 31/01/2020 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany | ||
| 4 | EUCTR2019-001430-33-GB (EUCTR) | 05/05/2020 | 21/02/2020 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 INN or Proposed INN: to be confirmed Product Code: GS-4875 INN or Proposed INN: to be confirmed | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 2 | United States;Czechia;Austria;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Poland;Australia;Germany | ||
| 5 | EUCTR2019-001430-33-IT (EUCTR) | 05/05/2020 | 27/01/2021 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis - FALCON | ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: GS-4875 Product Code: [GS-4875] Product Name: GS-4875 Product Code: [GS-4875] | GILEAD SCIENCES INCORPORATED | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czechia;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Poland;Australia;Germany | ||
| 6 | EUCTR2019-001430-33-FR (EUCTR) | 02/04/2020 | 20/02/2020 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany | ||
| 7 | NCT04130919 (ClinicalTrials.gov) | December 20, 2019 | 16/10/2019 | Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | Drug: Tilpisertib;Drug: Placebo | Gilead Sciences | NULL | Completed | 18 Years | N/A | All | 19 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Italy;Poland;Switzerland |